Medindia

X

Scientists Search for Therapeutic Synergy in Primary Effusion Lymphoma

by Bidita Debnath on  May 6, 2013 at 10:25 PM Research News   - G J E 4
A rare and fatal form of aggressive B-cell lymphoma is Primary effusion lymphoma (PEL), which is caused by Kaposi's sarcoma-associated herpesvirus (KSHV).
 Scientists Search for Therapeutic Synergy in Primary Effusion Lymphoma
Scientists Search for Therapeutic Synergy in Primary Effusion Lymphoma
Advertisement

The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies.

Advertisement
In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat multiple myeloma and cutaneous T cell lymphoma, respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors.

These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like